Your browser doesn't support javascript.
loading
Cross-reactive EBNA1 immunity targets alpha-crystallin B and is associated with multiple sclerosis.
Thomas, Olivia G; Bronge, Mattias; Tengvall, Katarina; Akpinar, Birce; Nilsson, Ola B; Holmgren, Erik; Hessa, Tara; Gafvelin, Guro; Khademi, Mohsen; Alfredsson, Lars; Martin, Roland; Guerreiro-Cacais, André Ortlieb; Grönlund, Hans; Olsson, Tomas; Kockum, Ingrid.
Afiliación
  • Thomas OG; Therapeutic Immune Design, Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institute, 171 76 Stockholm, Sweden.
  • Bronge M; Therapeutic Immune Design, Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institute, 171 76 Stockholm, Sweden.
  • Tengvall K; Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institute, 171 76 Stockholm, Sweden.
  • Akpinar B; Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, 75123 Uppsala, Sweden.
  • Nilsson OB; Therapeutic Immune Design, Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institute, 171 76 Stockholm, Sweden.
  • Holmgren E; Therapeutic Immune Design, Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institute, 171 76 Stockholm, Sweden.
  • Hessa T; Therapeutic Immune Design, Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institute, 171 76 Stockholm, Sweden.
  • Gafvelin G; Therapeutic Immune Design, Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institute, 171 76 Stockholm, Sweden.
  • Khademi M; Therapeutic Immune Design, Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institute, 171 76 Stockholm, Sweden.
  • Alfredsson L; Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institute, 171 76 Stockholm, Sweden.
  • Martin R; Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institute, 171 76 Stockholm, Sweden.
  • Guerreiro-Cacais AO; Institute of Environmental Medicine, Karolinska Institute, 171 77 Stockholm, Sweden.
  • Grönlund H; Therapeutic Immune Design, Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institute, 171 76 Stockholm, Sweden.
  • Olsson T; Institute of Experimental Immunology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.
  • Kockum I; Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institute, 171 76 Stockholm, Sweden.
Sci Adv ; 9(20): eadg3032, 2023 05 19.
Article en En | MEDLINE | ID: mdl-37196088
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por Virus de Epstein-Barr / Alfa-Cristalinas / Esclerosis Múltiple Tipo de estudio: Risk_factors_studies Límite: Animals Idioma: En Revista: Sci Adv Año: 2023 Tipo del documento: Article País de afiliación: Suecia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por Virus de Epstein-Barr / Alfa-Cristalinas / Esclerosis Múltiple Tipo de estudio: Risk_factors_studies Límite: Animals Idioma: En Revista: Sci Adv Año: 2023 Tipo del documento: Article País de afiliación: Suecia